MDAI Quote, Financials, Valuation and Earnings

InfuSystems Holdings has a net margin of -18.4% compared to Spectral AI's net margin of 2.76%. Spectral AI's return on equity of -4727.7% beat InfuSystems Holdings's return on equity of 4.33%.

Spectral AI has a consensus price target of $5.12, signalling upside risk potential of 316.26%. On the other hand InfuSystems Holdings has an analysts' consensus of $14.13 which suggests that it could grow by 183.64%. Given that Spectral AI has higher upside potential than InfuSystems Holdings, analysts believe Spectral AI is more attractive than InfuSystems Holdings.

Spectral AI has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.898, suggesting its more volatile than the S&P 500 by 89.81%.

Spectral AI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spectral AI pays -- of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.

Spectral AI quarterly revenues are $8.2M, which are smaller than InfuSystems Holdings quarterly revenues of $33.8M. Spectral AI's net income of -$1.5M is lower than InfuSystems Holdings's net income of $933K. Notably, Spectral AI's price-to-earnings ratio is -- while InfuSystems Holdings's PE ratio is 49.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spectral AI is 0.75x versus 0.80x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -18.4% compared to Spectral AI's net margin of -18.58%. Spectral AI's return on equity of -4727.7% beat Retractable Technologies's return on equity of -16.83%.

Spectral AI has a consensus price target of $5.12, signalling upside risk potential of 316.26%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Spectral AI has higher upside potential than Retractable Technologies, analysts believe Spectral AI is more attractive than Retractable Technologies.

Spectral AI has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

Spectral AI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spectral AI pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Spectral AI quarterly revenues are $8.2M, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Spectral AI's net income of -$1.5M is higher than Retractable Technologies's net income of -$1.9M. Notably, Spectral AI's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spectral AI is 0.75x versus 0.62x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -18.4% compared to Spectral AI's net margin of -1226.82%. Spectral AI's return on equity of -4727.7% beat VolitionRX's return on equity of --.

Spectral AI has a consensus price target of $5.12, signalling upside risk potential of 316.26%. On the other hand VolitionRX has an analysts' consensus of $2.92 which suggests that it could grow by 499.18%. Given that VolitionRX has higher upside potential than Spectral AI, analysts believe VolitionRX is more attractive than Spectral AI.

Spectral AI has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.463%.

Spectral AI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spectral AI pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Spectral AI quarterly revenues are $8.2M, which are larger than VolitionRX quarterly revenues of $474.5K. Spectral AI's net income of -$1.5M is higher than VolitionRX's net income of -$5.8M. Notably, Spectral AI's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spectral AI is 0.75x versus 34.23x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -18.4% compared to Spectral AI's net margin of -10.04%. Spectral AI's return on equity of -4727.7% beat Xtant Medical Holdings's return on equity of -35.34%.

Spectral AI has a consensus price target of $5.12, signalling upside risk potential of 316.26%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 329.98%. Given that Xtant Medical Holdings has higher upside potential than Spectral AI, analysts believe Xtant Medical Holdings is more attractive than Spectral AI.

Spectral AI has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.033, suggesting its less volatile than the S&P 500 by 103.341%.

Spectral AI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spectral AI pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Spectral AI quarterly revenues are $8.2M, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Spectral AI's net income of -$1.5M is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, Spectral AI's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spectral AI is 0.75x versus 0.46x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.